Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 15/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.56 |
| ▸ | PRKCH | P24723 | 1/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.56 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1145999 | 0.87 | PRKCQ (0.73) | PRKCQPRKCDPRKCHPRKCEEGFR | |
| SCHEMBL2981351 | 0.86 | PRKCQ (0.76) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL1146002 | 0.83 | PRKCQ (0.73) | PRKCQPRKCDPRKCHPRKCEEGFR | |
| SCHEMBL14024780 | 0.82 | KDR (0.61) | PRKCQPRKCDPRKCHPRKCECDK1 | |
| SCHEMBL2981616 | 0.80 | PRKCQ (0.74) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL2977505 | 0.80 | PRKCQ (0.79) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL1145403 | 0.79 | PRKCQ (0.58) | PRKCQPRKCDPRKCHPRKCECDK1 | |
| SCHEMBL12856910 | 0.77 | PRKCQ (0.55) | PRKCQPRKCDPRKCHPRKCEEGFR | |
| SCHEMBL1146471 | 0.75 | PRKCQ (0.59) | PRKCQPRKCDPRKCHPRKCEMAP2K1 | |
| SCHEMBL1146073 | 0.74 | PRKCQ (0.75) | PRKCQPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110028455-A1 | Indole-substituted 3-cyanopyridines As Kinase Inhibitors | WYETH LLC (US) | 2011-02-03 | — | — | US | claimed |
| EP-2229376-A1 | INDOLE-SUBSTITUTED 3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | claimed |
| WO-2009076571-A1 | INDOLE-SUBSTITUTED 3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | claimed |
| US-20110028455-A1 | Indole-substituted 3-cyanopyridines As Kinase Inhibitors | WYETH LLC (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028455-A1 | Indole-substituted 3-cyanopyridines As Kinase Inhibitors | WYETH LLC (US) | 2011-02-03 | — | — | US | disclosed |
| US-20110028455-A1 | Indole-substituted 3-cyanopyridines As Kinase Inhibitors | WYETH LLC (US) | 2011-02-03 | — | — | US | disclosed |
| EP-2229376-A1 | INDOLE-SUBSTITUTED 3-CYANOPYRIDINES AS KINASE INHIBITORS | Wyeth LLC (US) | 2010-09-22 | — | — | EP | disclosed |
| WO-2009076571-A1 | INDOLE-SUBSTITUTED 3-CYANOPYRIDINES AS KINASE INHIBITORS | WYETH (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110028455-A1 | Indole-substituted 3-cyanopyridines As Kinase Inhibitors | CNKSR1, CSNK1G3, GRK3 | PRKCQ 324/4885PRKCD 291/4885PRKCH 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.